Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, prospective study willing to evaluate AMH levels changes in response
to chemotherapy plus GnRHa.
In the present study we propose to determine AMH levels in breast cancer patients, aged
<40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim
to assess the role of AMH as surrogate marker of the preservation of ovarian reserve exerted
by GnRHa.